335 related articles for article (PubMed ID: 31476877)
1. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
[No Abstract] [Full Text] [Related]
2. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
De Miguel R; Rial-Crestelo D; Dominguez-Dominguez L; Montejano R; Esteban-Cantos A; Aranguren-Rivas P; Stella-Ascariz N; Bisbal O; Bermejo-Plaza L; Garcia-Alvarez M; Alejos B; Hernando A; Santacreu-Guerrero M; Cadiñanos J; Mayoral M; Castro JM; Moreno V; Martin-Carbonero L; Delgado R; Rubio R; Pulido F; Arribas JR;
EBioMedicine; 2020 May; 55():102779. PubMed ID: 32408111
[TBL] [Abstract][Full Text] [Related]
3. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
Lanzafame M; Lattuada E; Gottardo R; Piacentini D; Be G; Razzaboni E; Cattaneo P; Luise D; Vento S
Int J Antimicrob Agents; 2021 Mar; 57(3):106290. PubMed ID: 33513407
[No Abstract] [Full Text] [Related]
4. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.
Taiwo BO; Zheng L; Stefanescu A; Nyaku A; Bezins B; Wallis CL; Godfrey C; Sax PE; Acosta E; Haas D; Smith KY; Sha B; Van Dam C; Gulick RM
Clin Infect Dis; 2018 May; 66(11):1689-1697. PubMed ID: 29253097
[TBL] [Abstract][Full Text] [Related]
5. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
6. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
Ciccullo A; Borghi V; Giacomelli A; Cossu MV; Sterrantino G; Latini A; Giacometti A; De Vito A; Gennari W; Madeddu G; Capetti A; d'Ettorre G; Mussini C; Rusconi S; Di Giambenedetto S; Baldin G
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):234-237. PubMed ID: 34446677
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
[TBL] [Abstract][Full Text] [Related]
9. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.
Gianella S; Marconi VC; Berzins B; Benson CA; Sax P; Fichtenbaum CJ; Wilkin T; Vargas M; Deng Q; Oliveira MF; Moser C; Taiwo BO
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):e112-e114. PubMed ID: 30383591
[No Abstract] [Full Text] [Related]
10. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Benatti S; Valenti D; Callegaro A; Ripamonti D; Mussini C
BMC Infect Dis; 2017 Mar; 17(1):215. PubMed ID: 28302065
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
14. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
Calza L; Legnani G; Fulgaro C; Verucchi G; Bon I; Lazzarotto T; Viale P
J Acquir Immune Defic Syndr; 2022 Mar; 89(3):e30. PubMed ID: 34743087
[No Abstract] [Full Text] [Related]
15. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
Nyaku AN; Zheng L; Gulick RM; Olefsky M; Berzins B; Wallis CL; Godfrey C; Sax PE; Acosta EP; Haas DW; Smith KY; Sha BE; Van Dam CN; Taiwo BO;
J Antimicrob Chemother; 2019 May; 74(5):1376-1380. PubMed ID: 30668695
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China: Erratum.
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):516. PubMed ID: 36350800
[No Abstract] [Full Text] [Related]
17. HIV 101: fundamentals of antiretroviral therapy.
Saag MS
Top Antivir Med; 2019 Sep; 27(3):123-127. PubMed ID: 31634859
[TBL] [Abstract][Full Text] [Related]
18. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Tolerability of Tenofovir/Lamivudine/Dolutegravir among Antiretroviral Therapy Naive Human Immunodeficiency Virus Infected Patients of a Tertiary Care Center in Eastern India.
Sengupta D; Ghosh S; Pain S; Chatterjee N
J Assoc Physicians India; 2023 Sep; 71(9):72-74. PubMed ID: 38700305
[TBL] [Abstract][Full Text] [Related]
20. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Hidalgo-Tenorio C; Pasquau J; Vinuesa D; Ferra S; Terrón A; SanJoaquín I; Payeras A; Martínez OJ; López-Ruz MÁ; Omar M; de la Torre-Lima J; López-Lirola A; Palomares J; Blanco JR; Montero M; García-Vallecillos C
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]